If you purchase through associated links, we may earn a commission, which will help test our product. Learn more.
You’ve heard about chloroquine and hydroxychloroquine everywhere now, and all thanks to the novel coronavirus pandemic that’s shutting down countries around the world. It’s so popular for a reason: President Trump repeated a report he saw on the news that could be a game-changer and help us get rid of the disease.
The sad truth is that we have slightly reached a point where science can back it all up. There are limited studies suggesting that antimalarial drugs might help improve the general condition of some patients. And there are similarly limited studies that say it possibly doesn’t make a difference. Second, there is anecdotal evidence from patients who survived COVID-19 thanks to chloroquine therapy, just as there is anecdotal evidence that hydroxychloroquine can poison others who abuse the drug. And one user died because he took anything. that seemed like the miracle cure we communicated on TV.
Health experts warn us that hydroxychloroquine isn’t the miracle drug you’re looking for because science doesn’t have this idea. But even so, the Centers for Disease Control and Prevention (CDC) has published unusual rules about the drug on its official coronavirus pages. , which can easily be called misinformation. Fortunately, the CDC has now corrected the error.
The Food and Drug Administration (FDA) legalized the use of chloroquine a few days ago, which makes sense given that the World Health Organization (WHO) has included the drug in a mega-trial aimed at boosting the discovery of effective treatments for COVID. But the CDC released data on the drug’s dosage a few days ago, attributing it to anecdotal evidence and not peer-reviewed studies.
“Although the optimal dose and duration of hydroxychloroquine for the treatment of COVID-19 is unknown, some U. S. doctors have anecdotally reported” tactics for prescribing the drug, the CDC website said, via Reuters. The chairman of the National Advisory Commission on Rural Health, Dr. Jeffrey Colyer, wrote a rare op-ed in the Wall Street Journal last week explicitly citing the drug’s dosage.
This is not the kind of data you need to have, as other people will search for treatment based on the data in editorials or CDC pages.
Some professionals were quick to practice the language used through the CDC to describe the use of hydroxychloroquine in COVID-19 cases. “Why would the CDC publish anecdotes?” The dean of the Milken Institute School of Public Health at George Washington University asked Reuters. “It doesn’t make sense. This is very Array
Mayo Clinic cardiologist and director of the Windland Smith Rice Genetic Heart Rhythm Clinic, Dr. Michael Ackerman, warned his medical colleagues about the drug’s heart effects, which can lead to sudden death. to say those drugs are a matrix, but to look at the data from cardiologists and infectious disease specialists say [hydroxychloroquine] is absolutely without even mentioning this rare side effect,” Ackerman told NBC News.
A few days ago, Dr. Anthony Fauci, an infectious disease expert, tried to fool Fox anchors.
The CDC has now gotten rid of this express information about hydroxychloroquine from its website. “There are no drugs or other therapies approved by the U. S. Food and Drug Administration. “”The U. S. is in the U. S. to save it or treat COVID-19,” the page states. As for the debatable drug, the updated page reads: “Hydroxychloroquine and chloroquine are undergoing clinical trials. “It did not come with dosing instructions.
You can access the most recent edition of the page, which lists other potential drugs being studied for use in the COVID-19 remedy, at this link.
Chris Smith has been covering customer electronics since the iPhone revolutionized the industry in 2008. When he’s not writing about the latest tech news for BGR, he occasionally keeps a close eye on the Marvel Cinematic Universe and other successful franchises. Outside of work, watch it stream almost all new movie releases and TV screens as soon as they’re available.
BGR’s audience craves our state-of-the-art data on the newest generation and entertainment, as well as our detailed and authoritative reviews.
We advise our unwavering readers on some of the most productive products, the latest trends and the most engaging stories with continuous coverage, found on all major news platforms.
Founded in 2006
More than 2 billion visitors
100K items
Millions of readers helped